Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's ...

The HYPERION II is Bruker's versatile FT-IR microscope for research and development with flexible accessories and the possibility to combine Infrared Laser Imaging (QCL) and FT-IR in one instrument.

Bruker has entered into a strategic collaboration ... rapid first-line testing with the cost-effective, short time-to-result IR Biotyper for the detection and rule-out of HAI outbreaks, followed ...

At the ESCMID Global 2025 conference, Bruker Corporation’s BRKR Microbiology and Infection Diagnostics division has announced the expansion of its microbiology solutions into Next-Generation ...

Near IR and Raman molecular spectroscopy product lines. Bruker’s timsTOF platform continues its adoption in 4D proteomics, epiproteomics and multiomics. In 2023, the segment delivered strong ...

To listen to the webcast, investors can go to https://ir.bruker.com and click on the "Q1 2025 Earnings Webcast" hyperlink in the "Events & Presentations" section. A slide presentation will be ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of its microbiology solutions into Next-Generation Sequencing (NGS ...